Abstract
Background Endometriosis is a widespread disease in women of reproductive age. The disease often reduces life quality of women affected by symptoms like dysmenorrhea, dyspareunia or infertility. Diagnosis remains challenging and no causal treatments exist until now. The scientific literature indicates many immunological changes like reduced cytotoxicity of natural killer cells and macrophages or altered concentrations of cytokines or cell adhesion molecules in women with endometriosis. Research has been concentrated on immunological alterations in peripheral blood, endometrial tissue and peritoneal fluid of women with endometriosis. Yet, knowledge on immunological differences in menstrual effluent is scarce. The aim of this study was to investigate menstrual effluent of hormone-free women with endometriosis in comparison to age matched healthy controls regarding selected immunological parameters.
Methods 12 women with endometriosis and 11 healthy controls were included in the study. Menstrual effluent (ME) was collected using menstrual cups over a time period of 24 h, and venous blood samples (PB) were taken. Mononuclear cells were obtained from ME (MMC) and PB (PBMC) using density gradient centrifugation and analyzed using flow cytometry. Furthermore, concentrations of cell adhesion molecules (ICAM-I and VCAM-I) and cytokines (IL-6, IL-8 and TNF-α) were measured in centrifugation supernatant of ME and plasma of PB.
Results The comparison of MMC from women with endometriosis and healthy controls revealed a significantly lower frequency of perforin-positive cells among CD8+ T cells in endometriosis patients compared to healthy controls. No additional differences regarding frequencies of CD8+ or CD4+ T cells, regulatory T cells (Tregs), NK cell subsets or monocytic subsets could be detected between MMC or PBMC, of endometriosis patients and healthy controls. Comparing MMC with PBMC revealed that MMC contained significantly more B cells and significantly less T cells than PBMC. Among the T cells, the CD4/CD8 ratio was significantly higher in MMC, and Tregs were significantly less common in MMC. T cells and NK cells expressed significantly more CD69 in MMC., NK cells of the MMC were predominantly CD56bright/CD16dim and the CD56dim NK cell subset had a low frequency of perforin+ cells, in contrast to CD56dim NK cells of PBMC, which were predominantly perforin-positive. However, NKp46 was significantly more expressed on NK cells from MMC. Finally, the endometriosis group had significantly lower plasma ICAM-I concentrations than the control group. There were no significant differences in VCAM-1, IL-6, IL-8 or TNF-α between the two groups.
Conclusion MMC are distinctively different from PBMC and, thus, seem to be of endometrial origin. The CD8+ T cells from the ME were significantly less perforin-positive in endometriosis patients than in healthy controls, suggesting a reduced cytotoxic potential.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Schweizer-Arau-Foundation, Germany.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The concept and implementation of this study was approved by ethical committee of the Medical Faculty at LMU Munich (no. 17-695) and the study was performed in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request from the authors.